TY - JOUR

T1 - Pulmonary function is a strong predictor of 2-year overall survival and non-relapse mortality after allogenic hematopoietic cell transplantation

AU - Schierbeck, Frederikke

AU - Mortensen, Jann

AU - Andersen, Niels S.

AU - Friis, Lone S.

AU - Kornblit, Brian

AU - Petersen, Søren L.

AU - Schjødt, Ida

AU - Sengeløv, Henrik

N1 - Publisher Copyright: © 2022 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.

PY - 2023

Y1 - 2023

N2 - Objectives: The purpose of the study was to assess the validity of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) and of pulmonary comorbidity prior to HCT in terms of predicting non-relapse mortality (NRM) and overall survival (OS). Methods: In this retrospective single-center study of 663 consecutive adult recipients of HCT, we stratified patients into groups by pulmonary comorbidity: low-risk, intermediate-risk, and high-risk. The predictive value of this pulmonary comorbidity score (PCS) was compared to HCT-CI. Results: In univariate analysis, the HCT-CI and the PCS were associated with OS after transplantation when comparing patients in high-risk groups with patients in low-risk groups. Using the PCS, the hazard ratios (HRs) of the 2-year OS in the entire population and in the myeloablative conditioning (MAC) group were 1.98 (p <.001) and 3.27 (p <.001), respectively, whereas the HRs using the HCT-CI were 1.83 (p <.001) and 2.57 (p =.002). The 2-year NRM incidence in the three risk-groups in the entire population was significant using both indexes. In the MAC group, the 2-year NRM was significant using the PCS (p =.003), but not using the HCT-CI (p =.23). Conclusions: Our study suggest that pulmonary function alone is a strong predictor of 2-year OS and NRM after HCT.

AB - Objectives: The purpose of the study was to assess the validity of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) and of pulmonary comorbidity prior to HCT in terms of predicting non-relapse mortality (NRM) and overall survival (OS). Methods: In this retrospective single-center study of 663 consecutive adult recipients of HCT, we stratified patients into groups by pulmonary comorbidity: low-risk, intermediate-risk, and high-risk. The predictive value of this pulmonary comorbidity score (PCS) was compared to HCT-CI. Results: In univariate analysis, the HCT-CI and the PCS were associated with OS after transplantation when comparing patients in high-risk groups with patients in low-risk groups. Using the PCS, the hazard ratios (HRs) of the 2-year OS in the entire population and in the myeloablative conditioning (MAC) group were 1.98 (p <.001) and 3.27 (p <.001), respectively, whereas the HRs using the HCT-CI were 1.83 (p <.001) and 2.57 (p =.002). The 2-year NRM incidence in the three risk-groups in the entire population was significant using both indexes. In the MAC group, the 2-year NRM was significant using the PCS (p =.003), but not using the HCT-CI (p =.23). Conclusions: Our study suggest that pulmonary function alone is a strong predictor of 2-year OS and NRM after HCT.

KW - HCT OS NRM comorbidity

U2 - 10.1111/ejh.13869

DO - 10.1111/ejh.13869

M3 - Journal article

C2 - 36153797

AN - SCOPUS:85140214912

VL - 110

SP - 50

EP - 59

JO - Scandinavian Journal of Haematology

JF - Scandinavian Journal of Haematology

SN - 0902-4441

IS - 1

ER -